04.10.25 -- Oral Therapies Take Center Stage For PsO And PsA Treatment

Explore the use of X-ray inspection systems for the internal examination of pharmaceutical products, particularly non-transparent packaged drugs.

In the age of digital transformation, AI is no longer optional. Find out how to successfully integrate AI into your organization's operations for a competitive edge.

Equipment validation ensures that pharmaceutical equipment meets regulatory and quality standards. See how a structured process ensures compliance, reliability, and high product quality.

There's a need for continuous innovation to develop life-saving drugs and therapies. Uncover the key outcomes of embracing Pharma 4.0 — and how they ladder up to drive critical business strategies.

Developing high-volume autoinjectors for concentrated drugs presents challenges in delivery, absorption, and patient usability raises concerns about their practicality and long-term effectiveness.

Learn about active air sampling and the characteristics of various microbiological sampling methods that are designed to optimize collection efficiency.

Review the complexities of developing linkers – chemical moieties which attach a drug payload to an antibody – and considerations when identifying a CRO for ADC research and development.

Drug developers and manufacturers must address several key challenges, including formulation complexity, improving bioavailability of poorly soluble compounds, and optimizing drug release profiles.

The production of a highly concentrated monoclonal antibody requires many process steps. Discover how to achieve a final mAb concentration above 200 g/L while maintaining critical quality attributes.

Review the key trends and challenges shaping the CDMO industry as well as the tools helping a leading CDMO meet the growing demand for pediatric formulations and taste-masking solutions.

Find out how reality capture was used to create a digital twin 750,000-square-foot Pfizer campus to support asset reinduction to Maximo EAM, saving Pfizer 3,000 hours per year.

Explore how the ADC landscape is being reshaped by new drug product capabilities that enable end-to-end development and manufacturing of cytotoxic bioconjugates.